Wednesday, June 21, 2017 4:13:09 PM
http://www.pharmaceutical-journal.com/news-and-analysis/features/acting-on-the-potential-of-action-potentials-will-bioelectronic-medicines-be-the-next-biologics/20202049.article
http://endonovo.com/cytotronics-platform/ (ENDV has Multiple Platforms!)
http://endonovo.com/tvemf-vs-pemf/
http://nypost.com/2017/04/12/apple-has-a-secret-team-developing-diabetes-treatments/
https://www.google.com/amp/mobile.reuters.com/article/amp/idUSKCN10C1K8
http://smallcapexclusive.com/duggan-robert-picked-pulse-biosciences-inc-nasdaqplse-shares/
https://www.forbes.com/profile/robert-duggan/
ENDV is the leader Bio electronics further along than Apple & Google/GSK Galvani Bio sciences subsidiary, and Pulse Biosciences PLSE ran from $4-$35 ENDV will see a a legendary run in the coming weeks and months. My target is $4:00-$5:00 than up List to Nasdaq next double digit dollars.
PLSE market cap 460 Million. Robert Duggan the founder of PCYC sold for 21 Billion just took a 19% stake in PLSE
Apple Bio electronics Biz is intrinsically worth a billion or more.
Galvani Bio Sciences is worth Billion or more with Google/GSK ponied up 750 Million for research and development.
The President of ENDV has spent half his salary over the last 12 months buying open market shares of ENDV every week. At an average cost of .26 He owns close to 21 Million shares. Total insiders hold over 41 million shares.
I think this has the makings of gapping up for the weeks and months ahead and running hard all day and the coming weeks and months Double Digit Dollar sustained run possibly triple digit dollars
Bring on the epic short squeeze. & the Milestone updates.
ENDV and Why Square Waves? ( Bio Electronic Medicine )
Sine waves take too long to reach their peak intensity. The lower slew rate means that they are not effective in producing a cellular/tissue response.
Triangle and sawtooth waves also suffer from a lower slew rate, meaning that they are not effective in producing a cellular/tissue response.
Endonovo’s TVEMF device produces a patented square waveform, which was proven the most effective waveform to increase cell growth and the production of over 200 growth factors and cytokines.
Cytotronics™ Platform ( Biologics )
Our Cytotronics™ platform uses Time-Varying Electromagnetic Field (TVEMF) technology to expand and enhance the therapeutic properties of stem cells, immune cells and for use in tissue engineering. The goal of our Cytotronics™ platform is to create optimized cell-based therapies with greater therapeutic potential than the un-modulated cells currently being used in regenerative medicine.
The origins of our Cytotronics™ platform dates back to experiments conducted at NASA to expand stem cells ex vivo and to create therapies that could be used to treat astronauts during long term space exploration. The results of those experiments revealed that Time-Varying Electromagnetic Fields (TVEMF) could be used to expand stem cells in the lab and resulted in the increased expression of dozens of genes related to cell growth, tumor suppression, cell adhesion and extracellular matrix production
PLSE about to break 52 week highs.
ENDV Bio Electronic Medicine platform has more potential with the 21 patents and counting.
PLSE 500 million market cap
ENDV 15 Million Market Cap
ENDV market cap is about to gel big time!
ENDV Has a Biologics and Bio Electronic Medicine Platform PLSE does not PLSE just has a Bio Electronic Medicine Platform. I firmly believe intrinsically ENDV has a lot more potential than PLSE.
$ENDV
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/25/2023 11:04:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:16:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM